NYSE:AGNAllergan Stock Price, Forecast & News

Allergan's stock was trading at $185.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AGN shares have decreased by 4.0% and is now trading at $178.15. View which stocks have been mosted impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 13 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allergan.

Allergan is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Allergan.

Allergan plc (NYSE:AGN) released its earnings results on Monday, February, 10th. The company reported $5.22 EPS for the quarter, topping the consensus estimate of $4.57 by $0.65. The company had revenue of $4.35 billion for the quarter, compared to analysts' expectations of $4.09 billion. Allergan had a positive return on equity of 9.82% and a negative net margin of 32.76%. The business's revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the business posted $4.29 EPS. View Allergan's earnings history.

Allergan declared a quarterly dividend on Wednesday, March 18th. Stockholders of record on Thursday, April 16th will be paid a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 annualized dividend and a yield of 1.66%. The ex-dividend date is Wednesday, April 15th. View Allergan's dividend history.

Allergan declared that its Board of Directors has approved a stock repurchase plan on Tuesday, January 29th 2019, which allows the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 4.1% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its shares are undervalued.

15 brokerages have issued 1 year target prices for Allergan's shares. Their forecasts range from $144.95 to $203.00. On average, they expect Allergan's share price to reach $180.08 in the next twelve months. This suggests a possible upside of 1.1% from the stock's current price. View analysts' price targets for Allergan.

Media coverage about AGN stock has trended very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allergan earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAllergan.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Horizon Therapeutics (HZNP), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Pacira Biosciences (PCRX) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan's stock is owned by many different institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.02%), Fulton Bank N.A. (0.00%) and Park National Corp OH (0.00%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Matthew M Walsh and William Meury. View institutional ownership trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Fulton Bank N.A., and Park National Corp OH. View insider buying and selling activity for Allergan.

AGN stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, and Matthew M Walsh. View insider buying and selling activity for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $178.15.

Allergan has a market capitalization of $58.61 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe. View additional information about Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]